MNPR · Monopar Therapeutics
$110.65
-0.23 (-0.21%)
At close · Aug 21
Market Cap
$831.24M
Shares
6.71M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$110.88
Open$122.01
Day$110.84–122.60
52W close$30.42–123.84
Avg vol 30d277K
Short int1.1M · 15.9% float · 3.4d
Short vol56%
DataAug 2024–Aug 2026
Filing10-Q · Aug 12
Raw chart and full-history price indicators begin at the captured split on Aug 13, 2024; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 12, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+51%
above
Price vs 50-day avg
+11%
above
RSI (14)
50
neutral
MACD trend
Negative
52-week position
86%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+5%
trailing
6-month return
+102%
trailing
YTD return
+70%
this year
Relative strength
+91%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $100 › 200d $73 — 50d above 200d
Institutional flow
Accumulating
+16% holders QoQ · +30 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
15.87% of float · ▼ -21.7% MoM · 3.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
95 holders — near 3-yr high, broad support
Squeeze score
66
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
75%
annualized · 1-yr
Max drawdown
−51%
past year
ATR
6.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+51%
Bullish
Price vs 50-day avg
+11%
Bullish
RSI (14)
50
Neutral
MACD trend
Negative
Bearish
52-week position
86%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $100 › 200d $73 — 50d above 200d
Institutional flow
Accumulating
+16% holders QoQ · +30 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
15.87% of float · ▼ -21.7% MoM · 3.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
95 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $30
Now $111 · 86%
Range high $124
vs 200-day avg +51%
vs 50-day avg +11%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MNPR
this stock
Monopar Therapeutics
|
$831.24M | +69.8% | — | — | 15.9% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
Raw-price comparisons begin at the captured split on Aug 13, 2024; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MNPR | +0.4% | +4.9% | +102.3% | +2.3% | +69.8% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +2.4% | +1.6% | +91.2% | +0.3% | +58.0% |
Key facts
CIK
1645469
CUSIP
61023L207
13F (30d)
94 filings
93 filers
Visit website
Investor relations